Kenvue Inc. (KVUE), headquartered in Skillman, New Jersey, is a global consumer health company specializing in personal care, health, and wellness products. With a market cap of $44.79 billion, Kenvue offers a diverse portfolio of well-known brands across categories like skin health, oral care, and over-the-counter medicines. The company operates globally, providing trusted products to consumers in markets worldwide, competing with major consumer health companies in the industry.
Companies valued at $10 billion or more are classified as "large-cap" stocks, and Kenvue is a strong example. Kenvue’s focus on health and well-being positions it as a key player in improving daily lives through reliable and accessible healthcare solutions.
KVUE shares are trading marginally below their 52-week high of $23.47, which they hit on Sep. 10. The stock has gained 29.7% over the past three months, considerably outperforming the Consumer Staples Select Sector SPDR Fund (XLP), which has gained 9.3% over the same time frame.
In the longer term, KVUE is up 8.6% on a YTD basis, and the shares have gained 8.3% over the past 52 weeks. In comparison, the XLP has gained 16.5% in 2024 and rallied 16.7% over the past year.
KVUE has been trading above its 50-day- and 200-day moving averages since early August to confirm its bullish trend.
On Aug. 6, Kenvue's shares surged by more than 14.6% following a Q2 earnings report that surpassed Wall Street's expectations. Although the company saw a slight year-over-year decline, its net sales of $4 billion narrowly beat analysts' forecast of $3.93 billion. The company expects full-year earnings in the range of $1.10 to $1.20 per share.
Given the stock's strong recent price performance, analysts are moderately optimistic about KVUE's prospects. The stock has a consensus rating of "Moderate Buy" from 14 analysts in coverage. The mean price target is $22.75, which indicates that the stock trades at a premium.
On the date of publication, Rashmi Kumari did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
